| Barchart Demo Center |
$2.29
-0.05 (-2.14%)
as of May 17, 2024
as of May 17, 2024
| Last | 2.29 |
|---|---|
| Change | -0.05 (-2.14%) |
| Open | 2.28 |
| Prev. Close | 2.34 |
| Today's Range |
2.23
2.40
|
| 52wk Range |
1.30
13.20
|
| Volume | 34,100 |
| Avg Volume | 2,454,635 |
| Sector | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Name | Today | 3-Month | 1-Year |
|---|---|---|---|
| CYCC |
 -2.14% |
 -8.03% |
-76.51% |
| DJIA |
 +0.34% |
 +3.13% |
+19.70% |
| S&P 500 |
+0.12% |
+2.83% |
+27.52% |
Key Statistics
| Annual EPS | -22.44 |
|---|---|
| Dividend Yield | 0.00% |
| P/E Ratio | N/A |
| Market Capitalization, $K | 4,160 |
| Weighted Alpha | -77.70 |
| Standard Deviation | -0.13 |
| Profit Margin | -4,401.34% |
| Beta | 0.54 |
Growth Rates
| YTD | -14.23% | |||
| 1-Year | -75.82% | |||
| 3-Year | -97.98% | |||
| 5-Year | -98.98% | |||
| 10-Year | -99.98% |
Opinion
| Sell | Hold | Buy |
Recent Headlines
Cyclacel Pharmaceuticals to Release First Quarter 2024
GlobeNewswire - Wed May 08, 08:15AM CDT
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;(full story)
Cyclacel Pharmaceuticals Announces Closing of $8.0
GlobeNewswire - Thu May 02, 03:30PM CDT
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;(full story)
Cyclacel Pharmaceuticals Announces $8.0 Million
GlobeNewswire - Tue Apr 30, 06:00AM CDT
BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;(full story)
Cyclacel Pharmaceuticals to Present New Clinical Data
GlobeNewswire - Mon Apr 01, 08:15AM CDT
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid...(full story)
Cyclacel Pharmaceuticals Reports Fourth Quarter and
GlobeNewswire - Tue Mar 19, 03:05PM CDT
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – ...(full story)